CA2517020A1 - Dihydropteridinones, method for the production and use thereof in the form of drugs - Google Patents
Dihydropteridinones, method for the production and use thereof in the form of drugs Download PDFInfo
- Publication number
- CA2517020A1 CA2517020A1 CA002517020A CA2517020A CA2517020A1 CA 2517020 A1 CA2517020 A1 CA 2517020A1 CA 002517020 A CA002517020 A CA 002517020A CA 2517020 A CA2517020 A CA 2517020A CA 2517020 A1 CA2517020 A1 CA 2517020A1
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- aryl
- denotes
- optionally
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract 3
- 238000004519 manufacturing process Methods 0.000 title claims 2
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 4
- 150000001875 compounds Chemical class 0.000 claims 14
- 229910052739 hydrogen Inorganic materials 0.000 claims 9
- 239000001257 hydrogen Substances 0.000 claims 9
- 125000005915 C6-C14 aryl group Chemical group 0.000 claims 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 7
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 5
- 239000002253 acid Substances 0.000 claims 5
- 125000005842 heteroatom Chemical group 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- -1 piperazinylcarbonyl Chemical group 0.000 claims 4
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 3
- 125000005974 C6-C14 arylcarbonyl group Chemical group 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 150000002829 nitrogen Chemical group 0.000 claims 3
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 125000002757 morpholinyl group Chemical group 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 1
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 claims 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 1
- 125000006710 (C2-C12) alkenyl group Chemical group 0.000 claims 1
- 125000006711 (C2-C12) alkynyl group Chemical group 0.000 claims 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 230000001028 anti-proliverative effect Effects 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 1
- 125000004185 ester group Chemical group 0.000 claims 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 230000007062 hydrolysis Effects 0.000 claims 1
- 238000006460 hydrolysis reaction Methods 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000006217 methyl sulfide group Chemical group [H]C([H])([H])S* 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000005592 polycycloalkyl group Polymers 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Transplantation (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
The present invention relates to new dihydropteridinones of general formula (I) (see formula I) wherein the groups L and R1- R5 have the meanings given in the claims and specification, the isomers thereof, processes for preparing these dihydropteridinones and the use thereof as pharmaceutical compositions.
Claims (12)
1) Compounds of general formula (I), wherein R1, R2 which may be identical or different, denote hydrogen or optionally substituted C1-C6-alkyl, or R1 and R2 together denote a 2- to 5-membered alkyl bridge which may contain 1 to 2 heteroatoms, R3 denotes hydrogen or a group selected from among optionally substituted C1-C12-alkyl, C2-C12-alkenyl, C2-C12-alkynyl and C6-C14-aryl, or a group selected from among optionally substituted and/or bridged C3-C12-cycloalkyl, C3-C12-cycloalkenyl, C7-C12-polycycloalkyl, C7-C12-polycycloalkenyl, C5-C12-spirocycloalkyl, C3-C12-heterocycloalkyl which contains 1 to 2 heteroatoms, and C3-C12-heterocycloalkenyl which contains 1 to 2 heteroatoms, or R1 and R3 or R2 and R3 together denote a saturated or unsaturated C3-C4-alkyl bridge which may contain 1 heteroatom, R4 denotes a group selected from among hydrogen, -CN, hydroxy, -NR6R7 and halogen, or a group selected from among optionally substituted C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C5-alkyloxy, C2-C5-alkenyloxy, C2-C5-alkynyloxy, C1-C6-alkylthio, C1-C6-alkylsulphoxo and C1-C6-alkylsulphonyl, L denotes a linker selected from among optionally substituted C2-C10-alkyl, C2-C10-alkenyl, C6-C14-aryl, -C2-C4-alkyl-C6-C14-aryl, -C6-C14-aryl-C1-C4-alkyl, optionally bridged C3-C12-cycloalkyl and heteroaryl which contains 1 or 2 nitrogen atoms, n denotes 0 or 1 m denotes 1 or 2 R5 denotes a group selected from among optionally substituted morpholinyl, piperidinyl, piperazinyl, piperazinylcarbonyl, pyrrolidinyl, tropenyl, R8-diketomethylpiperazinyl, sulphoxomorpholinyl, sulphonylmorpholinyl, thiomorpholinyl, -NR8R9 and azacycloheptyl, R6, R7 which may be identical or different, denote hydrogen or C1-C4-alkyl, and R8, R9 denote unsubstituted nitrogen substituents at R5, which may be identical or different, denote either hydrogen or a group selected from among C1-C6-alkyl, -C1-C4-alkyl-C3-C10-cycloalkyl, C3-C10-cycloalkyl, C6-C14-aryl, -C1-C4-alkyl-C6-C14-aryl, pyranyl, pyridinyl, pyrimidinyl, C1-C4-alkyloxycarbonyl, C6-C14-arylcarbonyl, C1-C4-alkylcarbonyl, C6-C14-arylmethyloxycarbonyl, C6-C14-arylsulphonyl, C1-C4-alkylsulphonyl and C6-C14-aryl-C1-C4-alkylsulphonyl, optionally in the form of the tautomers, the racemates, the enantiomers, the diastereomers and the mixtures thereof, and optionally the pharmacologically acceptable acid addition salts thereof.
2) Compounds of general formula (I), wherein R1 to R4, R6 and R7 are as hereinbefore defined, and L denotes a linker selected from among optionally substituted C2-C10-alkyl, C2-C10-alkenyl, C6-C14-aryl, -C2-C4-alkyl-C6-C14-aryl, -C6-C14-aryl-C1-C4-alkyl, optionally bridged C3-C12-cycloalkyl and heteroaryl which contains 1 or 2 nitrogen atoms n denotes 1 m denotes 1 or 2 R5 denotes a group which is bound to L via a nitrogen atom, selected from among optionally substituted morpholinyl, piperidinyl, R8-piperazinyl, pyrrolidinyl, tropenyl, R8-diketomethylpiperazinyl, sulphoxomorpholinyl, sulphonylmorpholinyl, thiomorpholinyl, -NR8R9 and azacycloheptyl, R8, R9 denote unsubstituted nitrogen substituents at R5, which may be identical or different, hydrogen or a group selected from among C1-C6-alkyl, -C1-C4-alkyl-C3-C10-cycloalkyl, C3-C10-cycloalkyl, C6-C14-aryl, -C1-C4-alkyl-C6-C14-aryl, pyranyl, pyridinyl, pyrimidinyl, C1-C4-alkyloxycarbonyl, C6-C14-arylcarbonyl, C1-C4-alkylcarbonyl, C6-C14-arylmethyloxycarbonyl, C6-C14-arylsulphonyl, C1-C4-alkylsulphonyl and C6-C14-aryl-C1-C4-alkylsulphonyl, optionally in the form of the tautomers, the racemates, the enantiomers, the diastereomers and the mixtures thereof, and optionally the pharmacologically acceptable acid addition salts thereof.
3) Compounds according to claim 1, wherein R1 to R4, R6 and R7 are as hereinbefore defined, L denotes a linker selected from among optionally substituted C2-C10-alkyl, C2-C10-alkenyl, C6-C14-aryl, -C2-C4-alkyl-C6-C14-aryl, -C6-C14-aryl-C1-C4-alkyl, optionally bridged C3-C12-cycloalkyl and heteroaryl which contains 1 or 2 nitrogen atoms n denotes 0 or 1 m denotes 1 or 2 R5 denotes a group which is bound to L via a carbon atom, selected from among R8 - piperidinyl, R8R9-piperazinyl, R8-pyrrolidinyl, R8-piperazinylcarbonyl, R8-tropenyl, R8-morpholinyl and R8-azacycloheptyl, and R8, R9 denote unsubstituted nitrogen substituents at R5, which may be identical or different, hydrogen or a group selected from among C1-C6-alkyl, -C1-C4-alkyl-C3-C10-cycloalkyl, C3-C10-cycloalkyl, C6-C14-aryl, -C1-C4-alkyl-C6-C14-aryl, pyranyl, pyridinyl, pyrimidinyl, C1-C4-alkyloxycarbonyl, C6-C14-arylcarbonyl, C1-C4-alkylcarbonyl, C6-C14-arylmethyloxycarbonyl, C6-C14-arylsulphonyl, C1-C4-alkylsulphonyl and C6-C14-aryl-C1-C4-alkylsulphonyl, optionally in the form of the tautomers, the racemates, the enantiomers, the diastereomers and the mixtures thereof, and optionally the pharmacologically acceptable acid addition salts thereof.
4) Compounds according to one of claims 1 to 3, wherein L, m, n and R3 to R9 are as hereinbefore defined, and R1, R2 which may be identical or different, denote a group selected from among hydrogen, Me, Et, Pr, or R1 and R2 together form a C2-C4-alkyl bridge, optionally in the form of the tautomers, the racemates, the enantiomers, the diastereomers and the mixtures thereof, and optionally the pharmacologically acceptable acid addition salts thereof.
5) Compounds according to one of claims 1 to 4, wherein R1, R2, m, n and R5 to R8 are as hereinbefore defined, and R3 denotes a group selected from among optionally substituted C1-C10-alkyl, C3-C7-cycloalkyl, C3-C6-heterocycloalkyl and C6-C14-aryl or R1 and R3 or R2 and R3 together denote a saturated or unsaturated C3-C4-alkyl bridge which may contain 1 to 2 heteroatoms, R4 denotes a group selected from among hydrogen, OMe, OH, Me, Et, Pr, OEt, NHMe, NH2, F, CL, Br, O-propargyl, O-butynyl, CN, SMe, NMe2, CONH2, ethynyl, propynyl, butynyl and allyl, and L denotes a linker selected from among optionally substituted phenyl, phenylmethyl, cyclohexyl and branched C1-C6-alkyl, optionally in the form of the tautomers, the racemates, the enantiomers, the diastereomers and the mixtures thereof, and optionally the pharmacologically acceptable acid addition salts thereof.
6) Compound of formula I according to one of claims 1 to 5 for use as a pharmaceutical composition.
7) Compound of formula I according to one of claims 1 to 5 for use as a pharmaceutical composition with an antiproliferative activity.
8) Use of a compound of formula I according to one of claims 1 to 5 for preparing a pharmaceutical composition for the treatment and/or prevention of cancer, infections, inflammatory and autoimmune diseases.
9) Method of treating and/or preventing cancer, infections, inflammatory and autoimmune diseases, characterised in that a patient is given an effective quantity of a compound of formula I according to claims 1 to 4.
10) Pharmaceutical preparations, containing as active substance one or more compounds of general formula (I) according to one of claims 1 to 4 or the physiologically acceptable salts thereof, optionally combined with conventional excipients and/or carriers.
11) Process for preparing a compound of general formula (I), wherein R1-R5,m ,n and L have the meanings given in claims 1 to 5, characterised in that a compound of general formula (II) wherein R1-R3 have the meanings given in claims 1 to 4 and A is a leaving group, is reacted with an optionally substituted compound of general formula (III), wherein R4 has the meanings given in claims 1 to 5 and R10 denotes OH, NH-L-R5, -O-methyl, -O-ethyl, and then optionally the product of general formula (IV) wherein R1 to R4 has the meanings given in claims 1 to 5 and R10 denotes OH, -NH-L-R5, -O-methyl or -O-ethyl, optionally after previous hydrolysis of the ester group -COR10, is reacted with an amine of general formula (V) NH2-L-R5m (V) wherein R5 has the meanings given in claims 1 to 5.
12) Compound of formula (II), wherein R1-R3 have the meanings given in claims 1 to 5 and A is a leaving group.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2003/001935 WO2004076454A1 (en) | 2003-02-26 | 2003-02-26 | Dihydropteridinones, method for the production and use thereof in the form of drugs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2517020A1 true CA2517020A1 (en) | 2004-09-10 |
| CA2517020C CA2517020C (en) | 2012-06-26 |
Family
ID=32921552
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2517020A Expired - Fee Related CA2517020C (en) | 2003-02-26 | 2003-02-26 | Dihydropteridinones, method for the production and use thereof in the form of drugs |
Country Status (27)
| Country | Link |
|---|---|
| EP (1) | EP1599478B1 (en) |
| JP (1) | JP3876265B2 (en) |
| KR (1) | KR100983462B1 (en) |
| CN (2) | CN100537570C (en) |
| AT (1) | ATE361924T1 (en) |
| AU (1) | AU2003215591B2 (en) |
| BR (1) | BR0318145A (en) |
| CA (1) | CA2517020C (en) |
| CY (1) | CY1106752T1 (en) |
| DE (1) | DE50307267D1 (en) |
| DK (1) | DK1599478T3 (en) |
| EA (1) | EA008778B1 (en) |
| ES (1) | ES2287583T3 (en) |
| HK (1) | HK1089444A1 (en) |
| HR (1) | HRP20050735B1 (en) |
| IL (1) | IL170419A (en) |
| ME (1) | ME00376B (en) |
| MX (1) | MXPA05009068A (en) |
| NO (1) | NO332538B1 (en) |
| NZ (1) | NZ542498A (en) |
| PL (1) | PL226417B1 (en) |
| PT (1) | PT1599478E (en) |
| RS (1) | RS52386B (en) |
| SI (1) | SI1599478T1 (en) |
| TW (1) | TWI313600B (en) |
| UA (1) | UA80743C2 (en) |
| WO (1) | WO2004076454A1 (en) |
Cited By (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7414053B2 (en) | 2004-08-25 | 2008-08-19 | Boehringer Ingelheim International Gmbh | Dihydropteridione derivatives, process for their manufacture and their use as medicament |
| US7547780B2 (en) | 2004-08-25 | 2009-06-16 | Boehringer Ingelheim International Gmbh | Dihydropteridione intermediate compounds |
| US7709471B2 (en) | 2006-07-06 | 2010-05-04 | Astrazeneca Ab | Compounds |
| US7728134B2 (en) | 2004-08-14 | 2010-06-01 | Boehringer Ingelheim International Gmbh | Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament |
| US7750152B2 (en) | 2003-02-26 | 2010-07-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Intermediate compounds for making dihydropteridinones useful as pharmaceutical compositions and processes of making the same |
| US7759485B2 (en) | 2004-08-14 | 2010-07-20 | Boehringer Ingelheim International Gmbh | Process for the manufacture of dihydropteridinones |
| US7759347B2 (en) | 2004-06-21 | 2010-07-20 | Boehringer Ingelheim International Gmbh | 2-benzylaminodihydropteridinones, process for their manufacture and use thereof as medicaments |
| US8058270B2 (en) | 2004-08-14 | 2011-11-15 | Boehringer Ingelheim International Gmbh | Dihydropteridinones for the treatment of cancer diseases |
| USRE43115E1 (en) | 2004-12-02 | 2012-01-17 | Boehringer Ingelheim International Gmbh | Process for the manufacture of fused piperazin-2-one derivatives |
| CN101379064B (en) * | 2006-02-08 | 2012-01-25 | 贝林格尔·英格海姆国际有限公司 | Trihydrochloride forms of a dihydropteridinone derivative and processes for preparation |
| US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| US8143247B2 (en) | 2004-08-14 | 2012-03-27 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
| US8193188B2 (en) | 2004-07-09 | 2012-06-05 | Boehringer Ingelheim International Gmbh | Methods of using pyridodihydropyrazinones |
| US8329695B2 (en) | 2007-08-03 | 2012-12-11 | Boehringer Ingelheim International Gmbh | Crystalline form of the free base N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7r)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide |
| US8410100B2 (en) | 2007-02-01 | 2013-04-02 | Boehringer Ingelheim International Gmbh | Pteridinone derivatives as PI3-kinases inhibitors |
| US8445675B2 (en) | 2004-08-14 | 2013-05-21 | Boehringer Ingelheim International Gmbh | Storage stable perfusion solution for dihydropteridinones |
| US8546566B2 (en) | 2010-10-12 | 2013-10-01 | Boehringer Ingelheim International Gmbh | Process for manufacturing dihydropteridinones and intermediates thereof |
| US9133199B2 (en) | 2007-09-28 | 2015-09-15 | Cyclacel Limited | Pyrimidine derivatives as protein kinase inhibitors |
| AU2012256410B2 (en) * | 2006-02-08 | 2016-04-28 | Boehringer Ingelheim International Gmbh | Trihydrochloride forms of a dihydropteridinone derivative and processes for preparation |
| US9358233B2 (en) | 2010-11-29 | 2016-06-07 | Boehringer Ingelheim International Gmbh | Method for treating acute myeloid leukemia |
| US9370535B2 (en) | 2011-05-17 | 2016-06-21 | Boehringer Ingelheim International Gmbh | Method for treatment of advanced solid tumors |
| US9867831B2 (en) | 2014-10-01 | 2018-01-16 | Boehringer Ingelheim International Gmbh | Combination treatment of acute myeloid leukemia and myelodysplastic syndrome |
| US9956225B2 (en) | 2013-07-26 | 2018-05-01 | Boehringer Ingelheim International Gmbh | Treatment of myelodysplastic syndrome |
Families Citing this family (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008510771A (en) | 2004-08-27 | 2008-04-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Dihydropteridinone, process for its preparation and its use as a pharmaceutical agent |
| DE602005023333D1 (en) | 2004-10-15 | 2010-10-14 | Takeda Pharmaceutical | KINASE INHIBITORS |
| SI1948180T1 (en) | 2005-11-11 | 2013-06-28 | Boehringer Ingelheim International Gmbh | Combination treatment of cancer comprising egfr/her2 inhibitors |
| TW200804389A (en) | 2006-02-14 | 2008-01-16 | Vertex Pharma | Dihydrodiazepines useful as inhibitors of protein kinases |
| JP2009537500A (en) * | 2006-05-19 | 2009-10-29 | アストラゼネカ アクチボラグ | Dihydropteridine compounds as growth inhibitors |
| SG158147A1 (en) | 2006-10-09 | 2010-01-29 | Takeda Pharmaceutical | Kinase inhibitors |
| US8883790B2 (en) | 2006-10-12 | 2014-11-11 | Astex Therapeutics Limited | Pharmaceutical combinations |
| EP2073803B1 (en) | 2006-10-12 | 2018-09-19 | Astex Therapeutics Limited | Pharmaceutical combinations |
| JP5513118B2 (en) | 2006-10-19 | 2014-06-04 | シグナル ファーマシューティカルズ，エルエルシー | Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors |
| EP2102210B1 (en) * | 2006-12-14 | 2011-02-09 | Vertex Pharmceuticals Incorporated | Compounds useful as protein kinase inhibitors |
| CA2673472A1 (en) | 2006-12-21 | 2008-07-03 | Vertex Pharmaceuticals Incorporated | 5-cyan0-4- (pyrrolo) [2, 3b] pyridine-3-yl) -pyrimidine derivatives useful as protein kinase inhibitors |
| US20090291938A1 (en) * | 2007-11-19 | 2009-11-26 | Takeda Pharmaceutical Company Limited | Polo-like kinase inhibitors |
| US8598172B2 (en) | 2007-12-04 | 2013-12-03 | Nerviano Medical Sciences S.R.L. | Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors |
| EP2100894A1 (en) | 2008-03-12 | 2009-09-16 | 4Sc Ag | Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors |
| EP2112152A1 (en) | 2008-04-22 | 2009-10-28 | GPC Biotech AG | Dihydropteridinones as Plk Inhibitors |
| GB0807452D0 (en) * | 2008-04-24 | 2008-05-28 | Chroma Therapeutics Ltd | PLK inhibitors |
| KR20110033239A (en) * | 2008-06-23 | 2011-03-30 | 버텍스 파마슈티칼스 인코포레이티드 | Protein kinase inhibitors |
| PL2331092T3 (en) | 2008-08-21 | 2014-08-29 | Univ Johns Hopkins | Methods and compositions for administration of 3-halopyruvate and related compounds for the treatment of cancer |
| WO2010025073A1 (en) * | 2008-08-28 | 2010-03-04 | Takeda Pharmaceutical Company Limited | Dihydroimidazo [ 1, 5-f] pteridines as polo-like kinase inhibitors |
| US8110578B2 (en) | 2008-10-27 | 2012-02-07 | Signal Pharmaceuticals, Llc | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway |
| TWI432436B (en) | 2008-12-09 | 2014-04-01 | Gilead Sciences Inc | Modulators of toll-like receptors |
| CA2748181C (en) * | 2009-01-06 | 2019-07-16 | Nathanael S. Gray | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders |
| PT2442809T (en) | 2009-06-17 | 2016-12-06 | Vertex Pharma | Inhibitors of influenza viruses replication |
| NZ598384A (en) | 2009-09-14 | 2014-04-30 | Gilead Sciences Inc | Modulators of toll-like receptors |
| CN102020643A (en) * | 2009-09-22 | 2011-04-20 | 上海恒瑞医药有限公司 | dihydropteridine ketone derivative, and preparation method and medicinal application thereof |
| WO2011036566A1 (en) | 2009-09-25 | 2011-03-31 | Vertex Pharmaceuticals Incorporated | Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors |
| MX2012003476A (en) | 2009-09-25 | 2012-06-19 | Vertex Pharma | Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors. |
| SG10201500511TA (en) | 2009-10-26 | 2015-03-30 | Signal Pharm Llc | Methods Of Synthesis And Purification Of Heteroaryl Compounds |
| EP2325185A1 (en) | 2009-10-28 | 2011-05-25 | GPC Biotech AG | Plk inhibitor |
| PH12012501122A1 (en) * | 2009-12-23 | 2012-10-29 | Elan Pharm Inc | Pteridinones as inhibitors of polo-like kinase |
| US20120329803A1 (en) * | 2010-02-17 | 2012-12-27 | Boehringer Ingelheim International Gmbh | Dihydropteridinones, method for production and use thereof |
| CN102190669A (en) * | 2010-03-19 | 2011-09-21 | 江苏恒瑞医药股份有限公司 | Dihydro pteridinone derivatives, preparation method thereof and application thereof in medicines |
| WO2012027495A1 (en) | 2010-08-27 | 2012-03-01 | University Of The Pacific | Piperazinylpyrimidine analogues as protein kinase inhibitors |
| AU2011343642A1 (en) | 2010-12-16 | 2013-05-02 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
| US20130131069A1 (en) | 2011-05-13 | 2013-05-23 | Boehringer Ingelheim International Gmbh | Method for treatment of solid malignancies including advanced or metastatic solid malignancies |
| UA118010C2 (en) | 2011-08-01 | 2018-11-12 | Вертекс Фармасьютікалз Інкорпорейтед | INFLUENCES OF INFLUENZA VIRUS REPLICATION |
| MX357833B (en) | 2011-10-19 | 2018-07-26 | Signal Pharm Llc | Treatment of cancer with tor kinase inhibitors. |
| EP2776444A4 (en) * | 2011-11-10 | 2015-07-22 | Osi Pharmaceuticals Llc | Dihydropteridinones |
| CA3125862A1 (en) | 2011-12-02 | 2013-06-06 | Signal Pharmaceuticals, Llc | Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use |
| JP5807750B2 (en) * | 2012-01-05 | 2015-11-10 | トヨタ自動車株式会社 | Fastening device and fastening method |
| US8865716B2 (en) | 2012-02-23 | 2014-10-21 | Boehringer Ingelheim International Gmbh | Dihydropteridinones II |
| US9006226B2 (en) | 2012-02-23 | 2015-04-14 | Boehringer Ingelheim International Gmbh | Dihydropteridinones I |
| EA028462B1 (en) | 2012-02-24 | 2017-11-30 | СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Methods for treating advanced non-small cell lung cancer using tor kinase inhibitor combination therapy |
| AU2013203714B2 (en) | 2012-10-18 | 2015-12-03 | Signal Pharmaceuticals, Llc | Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity |
| US20140154304A1 (en) | 2012-11-30 | 2014-06-05 | Boehringer Ingelheim International Gmbh | Combination therapy with volasertib |
| NZ630467A (en) | 2013-01-16 | 2017-02-24 | Signal Pharm Llc | Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith |
| JP6052527B2 (en) * | 2013-02-21 | 2016-12-27 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Dihydropteridinone I |
| EP2958918B1 (en) | 2013-02-21 | 2016-12-07 | Boehringer Ingelheim International GmbH | Dihydropteridinones ii |
| CA2908742C (en) | 2013-04-17 | 2021-06-01 | Signal Pharmaceuticals, Llc | Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer |
| MY189663A (en) | 2013-04-17 | 2022-02-23 | Signal Pharm Llc | Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer |
| CN113730412A (en) | 2013-04-17 | 2021-12-03 | 西格诺药品有限公司 | Treatment of cancer with dihydropyrazino-pyrazines |
| AU2014253978B2 (en) | 2013-04-17 | 2019-06-06 | Signal Pharmaceuticals, Llc | Combination therapy comprising a TOR kinase inhibitor and a 5-Substituted Quinazolinone Compound for treating cancer |
| EP2986319A1 (en) | 2013-04-17 | 2016-02-24 | Signal Pharmaceuticals, LLC | Combination therapy comprising a tor kinase inhibitor and n-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer |
| CN105324381A (en) | 2013-04-17 | 2016-02-10 | 西格诺药品有限公司 | Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one |
| AU2014254053B2 (en) | 2013-04-17 | 2019-06-06 | Signal Pharmaceuticals, Llc | Treatment of cancer with Dihydropyrazino-Pyrazines |
| MX2015015880A (en) | 2013-05-29 | 2016-05-31 | Signal Pharm Llc | PHARMACEUTICAL COMPOSITIONS OF 7-(6-(2-HYDROXYPROPAN-2-YL)PYRIDIN -3-YL)-1-((TRANS)-4-METHOXYCYCLOHEXYL)-3,4-DIHYDROPYRAZINO[2,3-< i>B]PYRAZIN-2(1H)-ONE, A SOLID FORM THEREOF AND METHODS OF THEIR USE. |
| RS57541B1 (en) | 2013-11-13 | 2018-10-31 | Vertex Pharma | Methods of preparing inhibitors of influenza viruses replication |
| ES2741444T3 (en) | 2013-11-13 | 2020-02-11 | Vertex Pharma | Inhibitors of influenza virus replication |
| JP2017504651A (en) | 2014-01-31 | 2017-02-09 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | Use of diazepan derivatives |
| EP3099171A4 (en) * | 2014-01-31 | 2017-08-09 | Dana-Farber Cancer Institute, Inc. | Dihydropteridinone derivatives and uses thereof |
| US9718824B2 (en) | 2014-04-16 | 2017-08-01 | Signal Pharmaceuticals, Llc | Solid forms comprising 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, and a coformer, compositions and methods of use thereof |
| NZ714742A (en) | 2014-04-16 | 2017-04-28 | Signal Pharm Llc | Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use |
| JP2017511367A (en) | 2014-04-16 | 2017-04-20 | シグナル ファーマシューティカルズ，エルエルシー | 1-ethyl-7- (2-methyl-6- (1H-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino [2,3-b] pyrazine-2 Solid forms comprising (1H) -one and coforms, compositions thereof and methods of use |
| US9737535B2 (en) | 2014-04-16 | 2017-08-22 | Signal Pharmaceuticals, Llc | Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines |
| CN104003989B (en) * | 2014-05-26 | 2015-11-11 | 苏州明锐医药科技有限公司 | Fu Lasai for and the preparation method of intermediate |
| CA2954056C (en) | 2014-07-11 | 2020-04-28 | Gilead Sciences, Inc. | Modulators of toll-like receptors for the treatment of hiv |
| NZ629796A (en) | 2014-07-14 | 2015-12-24 | Signal Pharm Llc | Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use |
| CA2955009A1 (en) | 2014-07-14 | 2016-01-21 | Signal Pharmaceuticals, Llc | Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof |
| JP2017526741A (en) | 2014-08-08 | 2017-09-14 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | Diazepan derivatives and uses thereof |
| CN106793775B (en) * | 2014-08-08 | 2020-06-02 | 达纳-法伯癌症研究所股份有限公司 | Dihydropyrazinone derivatives and uses thereof |
| BR112017005100A2 (en) | 2014-09-16 | 2017-12-05 | Gilead Sciences Inc | Methods of Preparation of Toll-like Receptor Modulators |
| JP2017526730A (en) | 2014-09-16 | 2017-09-14 | ギリアード サイエンシーズ， インコーポレイテッド | Solid form of Toll-like receptor modulator |
| JP6857617B2 (en) | 2015-05-13 | 2021-04-14 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | Influenza virus replication inhibitor |
| WO2016183116A1 (en) | 2015-05-13 | 2016-11-17 | Vertex Pharmaceuticals Incorporated | Methods of preparing inhibitors of influenza viruses replication |
| EP3307728A4 (en) | 2015-06-12 | 2019-07-17 | Dana Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| AU2016319785C1 (en) | 2015-09-11 | 2021-04-01 | Dana-Farber Cancer Institute, Inc. | Acetamide thienotriazolodiazepines and uses thereof |
| JP2018526421A (en) | 2015-09-11 | 2018-09-13 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | Cyanothienotriazolodiazepines and their use |
| US10751306B2 (en) | 2015-11-06 | 2020-08-25 | The Johns Hopkins University | Methods of treating liver fibrosis by administering 3-bromopyruvate |
| AU2016361478B2 (en) | 2015-11-25 | 2020-09-10 | Dana-Farber Cancer Institute, Inc. | Bivalent bromodomain inhibitors and uses thereof |
| CN105801582A (en) * | 2016-04-12 | 2016-07-27 | 合肥工业大学 | Novel dihydro pteridinone derivative, preparing method thereof and application to medicine |
| DE102017005089A1 (en) | 2016-05-30 | 2017-11-30 | Bayer Pharma Aktiengesellschaft | Substituted 3,4-dihydroquinoxaline-2 (1H) -one |
| DE102017005091A1 (en) | 2016-05-30 | 2017-11-30 | Bayer Pharma Aktiengesellschaft | Substituted 3,4-dihydropyrido [2,3-b] pyrazine-2 (1H) -one |
| CN106977584B (en) * | 2017-04-19 | 2019-12-06 | 吉林大学 | Compound for targeted ubiquitination degradation of PLK1 and BRD4 proteins and application thereof |
| ES2959860T3 (en) | 2017-06-22 | 2024-02-28 | Celgene Corp | Treatment of hepatocellular carcinoma characterized by hepatitis B virus infection |
| WO2019126696A1 (en) | 2017-12-22 | 2019-06-27 | Dana-Farber Cancer Institute, Inc. | Nek inhibitors and methods of use |
| EP3743067A1 (en) | 2018-01-25 | 2020-12-02 | Boehringer Ingelheim International GmbH | Combination treatment of acute myeloid leukemia |
| US11034669B2 (en) | 2018-11-30 | 2021-06-15 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| CN110343109B (en) * | 2019-08-21 | 2021-11-23 | 郑州大学 | Dihydropyridone-sulfonamide derivative, pharmaceutically acceptable salt thereof, preparation method and application thereof |
| AU2023248848A1 (en) | 2022-04-08 | 2024-10-17 | Inhibrx Biosciences, Inc. | Dr5 agonist and plk1 inhibitor or cdk inhibitor combination therapy |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001019825A1 (en) * | 1999-09-15 | 2001-03-22 | Warner-Lambert Company | Pteridinones as kinase inhibitors |
| WO2002076985A1 (en) * | 2001-03-23 | 2002-10-03 | Smithkline Beecham Corporation | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases |
| HUP0401293A3 (en) * | 2001-09-04 | 2008-03-28 | Boehringer Ingelheim Pharma | Novel dihydropteridinones, method for producing the same and the use thereof as medicaments |
-
2003
- 2003-02-26 SI SI200330867T patent/SI1599478T1/en unknown
- 2003-02-26 DK DK03816028T patent/DK1599478T3/en active
- 2003-02-26 EP EP03816028A patent/EP1599478B1/en not_active Expired - Lifetime
- 2003-02-26 PL PL378168A patent/PL226417B1/en unknown
- 2003-02-26 UA UAA200509021A patent/UA80743C2/en unknown
- 2003-02-26 CA CA2517020A patent/CA2517020C/en not_active Expired - Fee Related
- 2003-02-26 ES ES03816028T patent/ES2287583T3/en not_active Expired - Lifetime
- 2003-02-26 ME MEP-2008-588A patent/ME00376B/en unknown
- 2003-02-26 CN CNB038260298A patent/CN100537570C/en not_active Expired - Fee Related
- 2003-02-26 RS YU20050648A patent/RS52386B/en unknown
- 2003-02-26 WO PCT/EP2003/001935 patent/WO2004076454A1/en active IP Right Grant
- 2003-02-26 EA EA200501222A patent/EA008778B1/en not_active IP Right Cessation
- 2003-02-26 MX MXPA05009068A patent/MXPA05009068A/en active IP Right Grant
- 2003-02-26 AU AU2003215591A patent/AU2003215591B2/en not_active Ceased
- 2003-02-26 BR BRPI0318145-6A patent/BR0318145A/en not_active Application Discontinuation
- 2003-02-26 PT PT03816028T patent/PT1599478E/en unknown
- 2003-02-26 JP JP2004568646A patent/JP3876265B2/en not_active Expired - Lifetime
- 2003-02-26 AT AT03816028T patent/ATE361924T1/en active
- 2003-02-26 KR KR1020057015805A patent/KR100983462B1/en not_active IP Right Cessation
- 2003-02-26 NZ NZ542498A patent/NZ542498A/en not_active IP Right Cessation
- 2003-02-26 CN CNA200810002434XA patent/CN101200457A/en active Pending
- 2003-02-26 DE DE50307267T patent/DE50307267D1/en not_active Expired - Lifetime
- 2003-03-03 TW TW092104404A patent/TWI313600B/en not_active IP Right Cessation
-
2005
- 2005-08-22 IL IL170419A patent/IL170419A/en not_active IP Right Cessation
- 2005-08-25 HR HRP20050735AA patent/HRP20050735B1/en not_active IP Right Cessation
- 2005-09-23 NO NO20054414A patent/NO332538B1/en not_active IP Right Cessation
-
2006
- 2006-09-07 HK HK06109960.1A patent/HK1089444A1/en not_active IP Right Cessation
-
2007
- 2007-07-24 CY CY20071100981T patent/CY1106752T1/en unknown
Cited By (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7750152B2 (en) | 2003-02-26 | 2010-07-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Intermediate compounds for making dihydropteridinones useful as pharmaceutical compositions and processes of making the same |
| US8003786B2 (en) | 2003-02-26 | 2011-08-23 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Dihydropteridinone compounds |
| US7816530B2 (en) | 2003-02-26 | 2010-10-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Piperazinyl compounds |
| US7786299B2 (en) | 2003-02-26 | 2010-08-31 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Methods for treating diseases or conditions using dihydropteridinone compounds |
| US7759347B2 (en) | 2004-06-21 | 2010-07-20 | Boehringer Ingelheim International Gmbh | 2-benzylaminodihydropteridinones, process for their manufacture and use thereof as medicaments |
| US8193188B2 (en) | 2004-07-09 | 2012-06-05 | Boehringer Ingelheim International Gmbh | Methods of using pyridodihydropyrazinones |
| US8445675B2 (en) | 2004-08-14 | 2013-05-21 | Boehringer Ingelheim International Gmbh | Storage stable perfusion solution for dihydropteridinones |
| US8138373B2 (en) | 2004-08-14 | 2012-03-20 | Boehringer Ingelheim International Gmbh | Process for the manufacture of dihydropteridinones |
| US7759485B2 (en) | 2004-08-14 | 2010-07-20 | Boehringer Ingelheim International Gmbh | Process for the manufacture of dihydropteridinones |
| US8591895B2 (en) | 2004-08-14 | 2013-11-26 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
| US8202867B2 (en) | 2004-08-14 | 2012-06-19 | Boehringer Ingelheim International Gmbh | Methods of using hydrates and polymorphs of 4-[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide |
| US7728134B2 (en) | 2004-08-14 | 2010-06-01 | Boehringer Ingelheim International Gmbh | Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament |
| US8143247B2 (en) | 2004-08-14 | 2012-03-27 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
| US8138341B2 (en) | 2004-08-14 | 2012-03-20 | Boehringer Ingelheim International Gmbh | Intermediate compounds useful for the manufacture of dihydropteridinones |
| US8034816B2 (en) | 2004-08-14 | 2011-10-11 | Boehringer Ingelheim International Gmbh | Hydrates and polymorphs of 4-[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament |
| US8058270B2 (en) | 2004-08-14 | 2011-11-15 | Boehringer Ingelheim International Gmbh | Dihydropteridinones for the treatment of cancer diseases |
| US7547780B2 (en) | 2004-08-25 | 2009-06-16 | Boehringer Ingelheim International Gmbh | Dihydropteridione intermediate compounds |
| US7414053B2 (en) | 2004-08-25 | 2008-08-19 | Boehringer Ingelheim International Gmbh | Dihydropteridione derivatives, process for their manufacture and their use as medicament |
| US7629460B2 (en) | 2004-08-25 | 2009-12-08 | Boehringer Ingelheim International Gmbh | Dihydropteridione derivatives, process for their manufacture and their use as medicament |
| US7700769B2 (en) | 2004-08-25 | 2010-04-20 | Boehringer Ingelheim International Gmbh | Dihydropteridione derivatives, process for their manufacture and their use as medicament |
| US7723517B2 (en) | 2004-08-25 | 2010-05-25 | Boehringer Ingelheim International Gmbh | Dihydropteridione derivatives, process for their manufacture and their use as medicament |
| US7807831B2 (en) | 2004-08-25 | 2010-10-05 | Boehringer Ingelheim International Gmbh | Dihydropteridione derivatives, process for their manufacture and their use as medicament |
| USRE43115E1 (en) | 2004-12-02 | 2012-01-17 | Boehringer Ingelheim International Gmbh | Process for the manufacture of fused piperazin-2-one derivatives |
| US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| US8188086B2 (en) | 2006-02-08 | 2012-05-29 | Boehringer Ingelheim International Gmbh | Specific salt, anhydrous and crystalline form of a dihydropteridione derivative |
| CN101379064B (en) * | 2006-02-08 | 2012-01-25 | 贝林格尔·英格海姆国际有限公司 | Trihydrochloride forms of a dihydropteridinone derivative and processes for preparation |
| US8664222B2 (en) | 2006-02-08 | 2014-03-04 | Boehringer Ingelheim International Gmbh | Specific salt, anhydrous and crystalline form of a dihydropteridione derivative |
| CN102093360B (en) * | 2006-02-08 | 2014-11-05 | 贝林格尔.英格海姆国际有限公司 | Process for preparing a dihydropteridinone derivative |
| AU2012256410B2 (en) * | 2006-02-08 | 2016-04-28 | Boehringer Ingelheim International Gmbh | Trihydrochloride forms of a dihydropteridinone derivative and processes for preparation |
| US7709471B2 (en) | 2006-07-06 | 2010-05-04 | Astrazeneca Ab | Compounds |
| US8410100B2 (en) | 2007-02-01 | 2013-04-02 | Boehringer Ingelheim International Gmbh | Pteridinone derivatives as PI3-kinases inhibitors |
| US8329695B2 (en) | 2007-08-03 | 2012-12-11 | Boehringer Ingelheim International Gmbh | Crystalline form of the free base N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7r)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide |
| US9493471B2 (en) | 2007-09-28 | 2016-11-15 | Cyclacel Limited | Pyrimidine derivatives as protein kinase inhibitors |
| US9133199B2 (en) | 2007-09-28 | 2015-09-15 | Cyclacel Limited | Pyrimidine derivatives as protein kinase inhibitors |
| US8546566B2 (en) | 2010-10-12 | 2013-10-01 | Boehringer Ingelheim International Gmbh | Process for manufacturing dihydropteridinones and intermediates thereof |
| US9358233B2 (en) | 2010-11-29 | 2016-06-07 | Boehringer Ingelheim International Gmbh | Method for treating acute myeloid leukemia |
| US9370535B2 (en) | 2011-05-17 | 2016-06-21 | Boehringer Ingelheim International Gmbh | Method for treatment of advanced solid tumors |
| US9956225B2 (en) | 2013-07-26 | 2018-05-01 | Boehringer Ingelheim International Gmbh | Treatment of myelodysplastic syndrome |
| US9867831B2 (en) | 2014-10-01 | 2018-01-16 | Boehringer Ingelheim International Gmbh | Combination treatment of acute myeloid leukemia and myelodysplastic syndrome |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2517020A1 (en) | Dihydropteridinones, method for the production and use thereof in the form of drugs | |
| CN102702184B (en) | Oxazolidinone derivative | |
| CA2458699A1 (en) | Novel dihydropteridinones, method for producing the same and the use thereof as medicaments | |
| JP2008505157A5 (en) | ||
| CA2637765A1 (en) | Benzamide and heteroarene derivatives | |
| NZ337861A (en) | N-heterocyclic derivatives for treating multiple sclerosis, HIV dementia, Parkinson's disease, meningitis, atherosclerosis, cancer, inflammatory skin diseases | |
| CA2446756A1 (en) | Thiazole compounds useful as inhibitors of protein kinase | |
| CA2575720A1 (en) | Pyrimidine derivatives | |
| AU2019362389B2 (en) | Compounds containing deuterium | |
| TW200738698A (en) | Organic compounds | |
| KR20180031036A (en) | 1,3,5-triazine derivatives and their use | |
| KR20150054945A (en) | Process for making thienopyrimidine compounds | |
| NZ592766A (en) | 1,4-dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them | |
| MA30260B1 (en) | 4-PHENYL-THIAZOLE-5-CARBOXYLIC ACIDS AND 4-PHENYL-THIAZOLE-5-CARBOXYLIC ACID AMIDES AS PLK INHIBITORS 1 | |
| JP2019504090A (en) | Solid state forms of dasatinib and their preparation process | |
| JP2012506908A5 (en) | ||
| JPH09124479A (en) | N,n'-di(aralkyl)-n,n'-di(2-azaaralkyl)-alkylenediamine and method for using it in pharmaceutical and cosmetic composition | |
| MX2022006990A (en) | Crystalline form of a 7h-benzo[7]annulene-2-carboxylic acid derivative. | |
| RU2004139041A (en) | APPLICATION OF HETEROARENCARBOXAMIDES AS DOPAMIN-D3 LIGANDS FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM | |
| JP2006502128A5 (en) | ||
| EP3992185B1 (en) | Hydrazone amide derivative and application thereof in preparation of medicaments for preventing and treating alopecia | |
| JP2018520167A (en) | Molten quinoline compounds as PI3K / mTOR inhibitors | |
| JP2005517634A5 (en) | ||
| US20070219204A1 (en) | Pharmaceutically active ornitihine derivatives, ammonium salts thereof and methods of making same | |
| WO2021062168A1 (en) | Synthetic sphingolipid inspired molecules with heteroaromatic appendages, methods of their synthesis and methods of treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20190226 |